ID

40434

Beskrivning

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661

Länk

https://clinicaltrials.gov/show/NCT02468661

Nyckelord

  1. 2019-01-17 2019-01-17 -
  2. 2020-04-20 2020-04-20 -
  3. 2020-04-25 2020-04-25 -
Rättsinnehavare

Novartis Pharmaceuticals

Uppladdad den

20 april 2020

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Non-Small Cell Lung Cancer NCT02468661

Eligibility Non-Small Cell Lung Cancer NCT02468661

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
locally advanced or metastatic nsclc
Beskrivning

NSCLC Locally advanced malignant neoplasm | NSCLC Neoplasm metastasis

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0677984
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C0027627
egfr mutation (l858r and /or ex19del)
Beskrivning

EGFR mutation | EGFR Exon 19 Deletion Mutation | EGFR L858R mutation

Datatyp

boolean

Alias
UMLS CUI [1]
C3266992
UMLS CUI [2]
C3274204
UMLS CUI [3]
C4289657
cmet amplification by fish (gcn ≥ 6),
Beskrivning

C-MET gene amplification FISH | c-met gene Copy number

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1711106
UMLS CUI [1,2]
C0162789
UMLS CUI [2,1]
C0072453
UMLS CUI [2,2]
C1707513
acquired resistance to egfr tki (1st or 2nd génération)
Beskrivning

Resistance Acquired EGFR TKI Generation

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0439661
UMLS CUI [1,3]
C0079411
ecog performance status (ps) ≤ 1.
Beskrivning

ECOG performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with 3rd generation tki
Beskrivning

EGFR-TKI Generation Third Prior treatment

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0079411
UMLS CUI [1,3]
C0205437
UMLS CUI [1,4]
C1514463
phaseii : prior treatment with any of the following agents:
Beskrivning

Phase II clinical trials | Prior treatment with following agents

Datatyp

boolean

Alias
UMLS CUI [1]
C0282460
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1514463
UMLS CUI [2,3]
C0332282
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
Beskrivning

Crizotinib | Inhibitor c-met | Inhibitor HGF targeted therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C2974289
UMLS CUI [2,1]
C1999216
UMLS CUI [2,2]
C0072453
UMLS CUI [3,1]
C1999216
UMLS CUI [3,2]
C0062534
UMLS CUI [3,3]
C2985566
concomitant egfr tki and platinum based chemotherapy as first line regimen.
Beskrivning

Concomitant therapy EGFR-TKI | Concomitant therapy Platinum-based Chemotherapy regimen | First line treatment

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C1443775
UMLS CUI [2,1]
C1707479
UMLS CUI [2,2]
C1514162
UMLS CUI [2,3]
C0392920
UMLS CUI [3]
C1708063
platinum-based chemotherapy as first line treatment
Beskrivning

First line Chemotherapy Platinum-Based

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C1514162

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02468661

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
NSCLC Locally advanced malignant neoplasm | NSCLC Neoplasm metastasis
Item
locally advanced or metastatic nsclc
boolean
C0007131 (UMLS CUI [1,1])
C0677984 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0027627 (UMLS CUI [2,2])
EGFR mutation | EGFR Exon 19 Deletion Mutation | EGFR L858R mutation
Item
egfr mutation (l858r and /or ex19del)
boolean
C3266992 (UMLS CUI [1])
C3274204 (UMLS CUI [2])
C4289657 (UMLS CUI [3])
C-MET gene amplification FISH | c-met gene Copy number
Item
cmet amplification by fish (gcn ≥ 6),
boolean
C1711106 (UMLS CUI [1,1])
C0162789 (UMLS CUI [1,2])
C0072453 (UMLS CUI [2,1])
C1707513 (UMLS CUI [2,2])
Resistance Acquired EGFR TKI Generation
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
C1443775 (UMLS CUI [1,1])
C0439661 (UMLS CUI [1,2])
C0079411 (UMLS CUI [1,3])
ECOG performance status
Item
ecog performance status (ps) ≤ 1.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
EGFR-TKI Generation Third Prior treatment
Item
prior treatment with 3rd generation tki
boolean
C1443775 (UMLS CUI [1,1])
C0079411 (UMLS CUI [1,2])
C0205437 (UMLS CUI [1,3])
C1514463 (UMLS CUI [1,4])
Phase II clinical trials | Prior treatment with following agents
Item
phaseii : prior treatment with any of the following agents:
boolean
C0282460 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0332282 (UMLS CUI [2,3])
Crizotinib | Inhibitor c-met | Inhibitor HGF targeted therapy
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
C2974289 (UMLS CUI [1])
C1999216 (UMLS CUI [2,1])
C0072453 (UMLS CUI [2,2])
C1999216 (UMLS CUI [3,1])
C0062534 (UMLS CUI [3,2])
C2985566 (UMLS CUI [3,3])
Concomitant therapy EGFR-TKI | Concomitant therapy Platinum-based Chemotherapy regimen | First line treatment
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
C1707479 (UMLS CUI [1,1])
C1443775 (UMLS CUI [1,2])
C1707479 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C0392920 (UMLS CUI [2,3])
C1708063 (UMLS CUI [3])
First line Chemotherapy Platinum-Based
Item
platinum-based chemotherapy as first line treatment
boolean
C1708063 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C1514162 (UMLS CUI [1,3])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial